High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Background The changes in nonalcoholic fatty liver disease (NAFLD) range over a wide spectrum, extending from steatosis to steatohepatitis (NASH). However, it has remained difficult to differentiate between NASH and nonprogressive NAFLD by clinical examination. We investigated the interrelationships between serum high-sensitivity C-reactive protein (hs-CRP) and the pathogenesis and progression of NASH.Methods Hs-CRP was measured in 100 patients with histologically verified NAFLD (29 with steatosis and 71 with NASH), and a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis was performed to measure the intrahepatic mRNA expressions of CRP and interleukin (IL)-6.Results The results of a multiple regression analysis revealed that in comparison with cases of steatosis, hs-CRP was significantly elevated (P = 0.0048) in cases of NASH. Furthermore, among patients with NASH, hs-CRP was significantly elevated in those with advanced fibrosis compared with that in those with mild fibrosis (P = 0.0384), even after adjustment for age, sex, presence of diabetes, body mass index, visceral fat area, subcutaneous fat area, homeostasis model assessment for insulin resistance, high-density lipoprotein cholesterol, triglyceride, and low-density lipoprotein cholesterol. The results of the RT-PCR analysis showed that intrahepatic mRNA expression of CRP, but not IL-6, was increased in patients with NASH compared with those with steatosis (P = 0.0228).Conclusions This is the first report to demonstrate consistent and profound elevation of hs-CRP in cases of NASH compared with in cases of simple nonprogressive steatosis. Our results suggest that hs-CRP may be a clinical feature that not only distinguishes NASH from simple nonprogressive steatosis but also indicates the severity of hepatic fibrosis in cases of NASH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CRP is predictive of NASH in patients with NAFLD and is related to the presence and severity of liver fibrosis [133].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [133]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Research works printed but not linked: 4
- JM Hui, 2004, Hepatology, 40, 46
- T Ono, 1999, J Jpn Diabetes Soc, 42, 1005
- JM Hui, 2003, Hepatology, 38, 420
- H Baumann, 1990, Mol Biol Med, 7, 147
Cited by
Items 201–300 of 300
Wang, H., Ye, J., Chen, Y., Sun, Y., Gong, X., Deng, H., Dong, Z., Xu, L., Li, X., & Zhong, B. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03778-2 · Cited by 9
“Previous studies have indicated that elevated hs-CRP levels are associated with an increased risk of advanced fibrosis [30], which can predict the severity of liver fibrosis in MASH.”
Jung, H., Kyun, M.-L., Kwon, J.-I., Kim, J., Kim, J.-K., Park, D., Lee, Y. B., & Moon, K.-S. (2024) · Biomaterials Science · doi:10.1039/d4bm00874j · Cited by 10
Ismaiel, A., Almonajjed, M. B., Cătană, C.-S., Popa, S., & Dumitrascu, D. L. (2025) · Archives of Medical Research · doi:10.1016/j.arcmed.2025.103350 · Cited by 8
Wang, Y., Chen, K., Yu, J., Tu, Y., Zhao, Y., Zhang, Y., Hu, Y., Yang, H. J., Yan, H., & Zheng, C. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04018-3 · Cited by 13
The Role of Elastography in Non-Alcoholic Fatty Liver Disease.
Constantinescu, C., Săndulescu, L., & Săftoiu, A. (2020) · PubMed Central · doi:10.12865/chsj.46.03.07 · Cited by 12
“In recent years, highly sensitive CRP (hs-CRP) has been evaluated in numerous studies as a diagnostic tool for the differentiation of NAFLD from NASH but also for the severity of liver fibrosis in patients with NASH [37,38].”
BackgroundBelalcazar, L. M., Papandonatos, G. D., Erar, B., Peter, I., Alkofide, H., Balasubramanyam, A., Brautbar, A., Kahn, S. E., Knowler, W. C., Ballantyne, C. M., et al. (2015) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.115.001192 · Cited by 9
“GCKR Leu446Pro is a common variant associated with reduced GCKR function, increased triglycerides, and CRP. Methods and Results—”
BackgroundInfluentialPοlyzos, S. A. (2012) · ImmunoGastroenterology · doi:10.7178/ig.20 · Cited by 7
Suk, K. T., Kim, D. Y., Sohn, K. M., & Kim, D. J. (2013) · Advances in clinical chemistry · doi:10.1016/b978-0-12-800096-0.00002-0 · Cited by 8
C reactive protein levels in non-alcoholic fatty liver disease
Doğru, T., Genç, H., & Bağcı, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.06.030 · Cited by 7
“Moreover, it seems that high concentrations of hsCRP are associated with extensive liver fibrosis in NASH [1].”
BackgroundInfluentialSerum thymosin beta4 as a noninvasive biomarker in patients with nonalcoholic steatohepatitis
Jiang, Y. Q., Han, T., Zhang, Z., Zhang, Y., & Qi, F. (2017) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2017.4690/2016 · Cited by 6
Carretero‐Gómez, J., Carrasco-Sánchez, F. J., Rodríguez, J. M. F., Escribano, P. P. C., Miramontes‐González, J. P., Seguí-Ripoll, J. M., Ena, J., & Arévalo‐Lorido, J. C. (2023) · Revista Clínica Española · doi:10.1016/j.rce.2022.11.007 · Cited by 5
Association of metabolic abnormalities and the risk of hepatic fibrosis
Fu, J., Yi, Y., Li, L., Shu, X., & Chang, Y. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00025-z · Cited by 6
Koufakis, T., Popovic, D. S., Papadopoulos, C. E., Γιουλεμέ, Ό., & Doumas, M. N. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2312239 · Cited by 5
Tan, C.-H., Al-Kalifah, N., Lee, W., Ser, K., Lee, Y.-C., & Chen, J. (2018) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2018.04.010 · Cited by 5
Mukherjee, S., Saha, S., Banerjee, U., Banerjee, A. K., & Banerjee, R. (2021) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/2876 · Cited by 8
Stéatopathie métabolique : prise en charge
Pariente, A. E. (2009) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2009.02.028 · Cited by 8
Kawasaki, K. (2016) · 薬理と治療 · Cited by 6
Bilgir, F. (2014) · Journal of Autacoids · doi:10.4172/2161-0479.1000108 · Cited by 4
“Nevertheless, while still inconclusive, several studies showed the association of NASH with elevated circulating levels of inflammatory biomarkers (C-reactive protein, tumor necrosis factor alpha, interleukin 6 (IL6), chemokine ligand, plasminogen activator inhibitor-1 (PAI-1) and fibrinogen [2,7-10]) and endothelial…”
BackgroundTanouti, I., Fellah, H., Haddaji, A., Zerrad, C., Tahiri, M., Badre, W., Nfaoui, K., Pineau, P., Benjelloun, S., & Ezzikouri, S. (2024) · International Journal of Immunogenetics · doi:10.1111/iji.12669 · Cited by 4
Maddineni, G., Obulareddy, S. J., Paladiya, R. D., Korsapati, R. R., Jain, S., Jeanty, H., Vikash, F., Tummala, N., Shetty, S., Ghazalgoo, A., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002276 · Cited by 5
Владимировна, Т. Л., Курбатова, И. В., Дуданова, О. П., Соколовская, А. А., & Шиповская, А. А. (2017) · Proceedings of the Karelian Research Centre of the Russian Academy of Sciences · doi:10.17076/eb568 · Cited by 5
Harden, J. E., Tabacu, L. M., & Reynolds, L. J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111047 · Cited by 4
Hung, Y.-H., Sritharan, R., Vohl, M., Ilkayeva, O., Biertho, L. D., Tchernof, A., White, P. J., & Sethupathy, P. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.20.457162 · Cited by 10
Zheng, J., Xie, D., Nong, Y., Jia, K., & Sha, D. (2026) · BMC Gastroenterology · doi:10.1186/s12876-025-04588-2 · Cited by 4
“C-reactive protein (CRP), an established marker of systemic inflammation, predicts progression to cirrhosis and hepatic decompensation [13].”
A Current Approach to Non-Alcoholic Steatohepatitis in Type 2 Diabetes Mellitus Patients
Stan, S. I., Biciusca, T., Biciuşcă, V., Cioboată, R., Mitrea, A., Clenciu, D., Ghenea, A. E., & Dănoiu, S. (2023) · Gastroenterology Insights · doi:10.3390/gastroent14030027 · Cited by 4
Skovgaard, E. T., de Zawadzki, A., Kimer, N., Busk, T. M., Karsdal, M. A., Leeming, D. J., & Møller, S. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.03.033 · Cited by 3
Ziemiański, P., Domienik‐Karłowicz, J., Cylke, R., Pruszczyk, P., Kosieradzki, M., & Lisik, W. (2019) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.14827 · Cited by 3
“In some studies, high sensivity C-reactive protein (hsCRP) was reported to be an independent risk factor for NAFLD[7-9].”
BackgroundLiver Fibrosis and Perihematomal Edema Growth in Primary Intracerebral Hemorrhage
Parikh, N. S., Jesudian, A. B., Kamel, H., Hanley, D. F., Ziai, W., Murthy, S. B., Hanley, D. F., Butcher, K., Davis, S. M., GREGSON, B. A., et al. (2020) · Neurocritical Care · doi:10.1007/s12028-020-01081-4 · Cited by 4
Associations between Pre-Bariatric High-Sensitivity C-Reactive Protein and Post-Surgery Outcomes
Jamialahmadi, T., Nematy, M., Bo, S., Ponzo, V., Jangjoo, A., Goshayeshi, L., Tasbandi, A., Nikiforov, N. G., & Sahebkar, A. (2021) · Diagnostics · doi:10.3390/diagnostics11040721 · Cited by 5
“Patients with liver steatosis showed increased hs-CRP levels independent of their BMI [66] and hs-CRP was reported as an obesity-independent marker of NAFLD severity [67,68].”
BackgroundNon-alcoholic steatosis/steatohepatitis – 2010
Hagymási, K., & Lengyel, G. (2010) · Orvosi Hetilap · doi:10.1556/oh.2010.28989 · Cited by 3
Pentraxin 3 (PTX3) as a Biomarker of Bone Disease
Choi, B., & Chang, E. (2016) · Exposure and Health · doi:10.1007/978-94-007-7745-3_40-1 · Cited by 3
Non-Invasive Assessment of the Liver – Serum Markers and Imaging Techniques
Mania, A., Kemnitz, P., Mazur‐Melewska, K., Figlerowicz, M., & Suzewski, W. (2011) · InTech eBooks · doi:10.5772/20293 · Cited by 3
“Furthermore, high levels of high-sensitivity CRP were found to be associated with extensive liver fibrosis in NASH [Yoneda et al. ,2007].”
BackgroundCardiovascular risk in pediatric nonalcoholic fatty liver disease: recent advances
Baskar, S., Jhaveri, S., & Alkhouri, N. (2015) · Clinical Lipidology · doi:10.2217/clp.15.26 · Cited by 3
El‐Sayyad, H. I., & Shahary, E. (2016) · Clinical and Experimental Pharmacology · doi:10.4172/2161-1459.1000220 · Cited by 4
Oda, E. (2008) · Circulation Journal · doi:10.1253/circj.cj-08-0532 · Cited by 3
Bhardwaj, S., & Sharma, V. (2025) · Indian Journal of Clinical Cardiology · doi:10.1177/26324636251383229 · Cited by 2
“8 The liver also plays a pivotal role in producing inflammatory mediators and markers of endothelial dysfunction.”
Inflammatory parameters and liver fibrosis in patients with steatosis: A cross-sectional analysis
Duarte, M. B., Czermainski, J. G. E. S., Ferreira, L. F., Tovo, C. V., & Carteri, R. B. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i3.111569 · Cited by 2
Non-alcoholic Fatty Liver Disease in Obesity
Ferolla, S. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-19821-7_13 · Cited by 2
The relationship between hepatic fibrosis and arterial stiffness in hemodialysis patients
Güzel, F. B., Öztürk, İ., Gişi, K., İspiroğlu, M., Akkuş, G., Erken, E., Altunören, O., & Güngör, Ö. (2021) · Seminars in Dialysis · doi:10.1111/sdi.13011 · Cited by 2
Frequency of Dyslipidemia in Patients Presenting with Nonalcoholic Fatty Liver Disease
Ullah, M. I., Lala, G.-E., Karim, R., Zaman, N., Jan, I., & Shahzadi, A. (2023) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2023171544 · Cited by 2
Ma, X., Li, B., Liu, Y., & Guo, X. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1534200 · Cited by 2
Cribado de la enfermedad hepática por depósito de grasa: cómo y a quién
Lantarón, Á. T., & García, J. C. (2011) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2010.11.010 · Cited by 6
Ajam, T., Chhaparia, A., Oman, Z., & MEHDIRAD, A. A. (2017) · doi:10.35841/cardiology.1.2.55-59 · Cited by 2
“These markers have been shown to decrease with statin therapy [44].”
BackgroundPentraxin 3 (PTX3) as a Biomarker of Liver Disease
Choi, B., & Chang, E. (2017) · Biomarkers in disease · doi:10.1007/978-94-007-7675-3_32 · Cited by 2
Pentraxin 3 (PTX3) as a Biomarker of Liver Disease
Choi, B., & Chang, E. (2016) · Biomarkers in disease · doi:10.1007/978-94-007-7742-2_32-1 · Cited by 7
Oda, E., & Watanabe, K. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2175-8 · Cited by 2
Dunn, W., & Schwimmer, J. B. (2008) · Hepatology · doi:10.1002/hep.22502 · Cited by 2
Xuan, Y., Wang, B., Xie, B., Cen, Y., Yu, S., & Yao, Q. Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-03528-0 · Cited by 1
“In a cross-sectional study conducted in Japan, Yoneda and co-workers investigated 100 patients with histologically confirmed NAFLD 53 .”
Nairz, J., Messner, A., Zollner-Kiechl, S., Kiechl‐Kohlendorfer, U., & Knoflach, M. (2026) · Metabolites · doi:10.3390/metabo16020108 · Cited by 2
El-Aziz, R. A., Alnaggar, A. R., Nabih, M. I., Ali, S. A. A., Khattab, H. M., & ELatty, S. A. (2020) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2020.93053 · Cited by 1
“reported for the first time a significant elevation of CRP in patients with NASH compared with those with simple steatosis [23].”
BackgroundObésité et maladie du foie gras non alcoolique
Anty, R., Patouraux, S., Tran, A., & Gual, P. (2014) · Obésité · doi:10.1007/s11690-014-0414-4 · Cited by 1
(2010) · The Internet Journal of Gastroenterology · doi:10.5580/15dd · Cited by 1
“A study in nonalcoholic steatohepatitis (NASH) also demonstrated elevation of hs-CRP (7) .”
BackgroundInflammatory and Anti-Inflammatory Mediators Secreted by Adipose Tissue
Tilg, H., & Moschen, A. R. (2009) · Oxidative stress and disease · doi:10.1201/9781420091311.ch4 · Cited by 1
Ashmawi, M. A. A. K. (2015) · Internal Medicine Open Access · doi:10.4172/2165-8048.1000191 · Cited by 1
“There were significant increases in hs-CRP in NASH patients in some studies [19,20] and no differences in another [21].”
BackgroundKobyliak, N. M., Dynnyk, O., & Kyriienko, D. (2016) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.5.69.2015.75179 · Cited by 5
Bölükbaş, F. F., İgnak, S., Demirel, Ö. Ü., Furuncuoğlu, Y., Mantar, F., Sertel, S. C., Sağlam, F., & Bölükbaş, C. (2017) · Anadolu Kliniği Tıp Bilimleri Dergisi · doi:10.21673/anadoluklin.297152 · Cited by 1
Kishan, T. V., & Indurti, S. (2022) · International Journal of Anatomy Radiology and Surgery · doi:10.7860/ijars/2022/51279.2730 · Cited by 1
Surrogate markers in non-alcoholic steatohepatitis
Ismaiel, A., & Dumitrascu, D. L. (2022) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2511 · Cited by 2
“According to one study, hs-CRP may be a clinical feature that differentiates NASH from simple non-progressive steatosis and also predicts the severity of hepatic fibrosis in NASH patients [23].”
BackgroundPentraxin 3 (PTX3) as a Biomarker of Bone Disease
Choi, B., & Chang, E. (2017) · Biomarkers in disease · doi:10.1007/978-94-007-7693-7_40 · Cited by 1
Farag, N. M., Hassanin, T. M., Abouelhassan, M. M. A., Alyaa, E., Latief, A. E., Nomeir, H. M., & Abdullah Fahmi, N. M. (2022) · Journal of Clinical Images and Medical Case Reports · doi:10.52768/2766-7820/1837 · Cited by 1
“Hs-CRP is used as a marker of lowgrade systemic inflammation and similar to our study, two studies found that hs-CRP levels were significantly higher in patients with NASH compared to those with simple steatosis and associated with advanced fibrosis which means the risk for NAFLD was increased as increased the level o…”
MethodAkhtar, S., & Khan, A. U. (2020) · Advanced Journal of Graduate Research · doi:10.21467/ajgr.9.1.46-58 · Cited by 1
“For instance, a Japanese study evaluated that high-sensitivity CRP levels were particularly elevated in NASH patients in contrast with patients of steatosis [83].”
BackgroundWho is benefited by one daily glass of wine?
Fujita, T. (2008) · Hepatology · doi:10.1002/hep.22466 · Cited by 1
Fisher, L. R. (2011) · SUNScholar (Stellenbosch University) · Cited by 1
Oda, E. (2010) · Ningen dock : official journal of the Japanese Society of Human Dry Dock · doi:10.11320/ningendock.24.1 · Cited by 1
BMI・腹囲径およびメタボリックシンドロームと消化器疾患の相関について -逆流性食道炎,食道裂孔ヘルニア,胆石,脂肪肝の4疾患での横断的検討-
曽山, ゆ., 山田, 亮., 西川, 晋., 岡村, 朋., 真田, 牧., 坂口, 玲., 伊東, 香., 松田, 武., 木長, 健., 三浦, 正., et al. (2010) · Ningen dock : official journal of the Japanese Society of Human Dry Dock · doi:10.11320/ningendock.24.1017
Is rosuvastatin effective for non‐alcoholic steatohepatitis with dyslipidemia?
Ono, M. (2012) · Hepatology Research · doi:10.1111/j.1872-034x.2012.01052.x
Oda, E., & Watanabe, K. (2008) · Circulation Journal · doi:10.1253/circj.72.861
Yoneda, M., Nozaki, Y., Endo, H., Fujita, K., & Nakajima, A. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2176-7
“In reply, to the Editor: We were pleased to read this useful comment concerning our recent article regarding high-sensitivity Creactive protein (hs-CRP) in nonalcoholic steatohepatitis (NASH) patients.(1) Patients with nonalcoholic fatty liver disease (NAFLD) are well known to have metabolic syndrome, and increases in…”
BackgroundMethodSelf-citationNon alcoholic fatty liver disease and its relationship with hsCRP in type 2 diabetes mellitus
Bhuyan, N., Gogoi, M., Todi, V. K., Pegu, A. K., & Das, A. K. (2014) · International Journal of Research in Medical Sciences · doi:10.5455/2320-6012.ijrms20141164
Pediatric nonalcoholic fatty liver
Casielles, M. D. A., & Fajardo, C. M. (2013) · Revista cubana de medicina general integral
Correa, M. L. M. (2017) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/25762
Non-alcoholic Fatty Liver Disease: What We Learn from Omics Studies
Katrinli, Ş., Özdil, K., Doğanay, G. D., & Doğanay, H. L. (2018) · InTech eBooks · doi:10.5772/intechopen.71025
“Acute phase protein High sensitive C-reactive protein (Hs-CRP) [56]”
BackgroundStatus of high sensitive C- reactive protein (hs-CRP) in NAFLD obese type-2 diabetic subjects
Singh, S. K., Sharma, D., Singh, N., Kumar, R., & Gautam, P. (2020) · International Journal of Clinical Biochemistry and Research · doi:10.18231/2394-6377.2018.0075
“Moreover added that hs-CRP could be a clinical feature that not only distinguishes (Non-alcoholic steatohepatitis) NASH from simple non-progressive steatosis but also indicates the severity of hepatic fibrosis.(25) Bilirubin levels may also be linked to NAFLD via fatty acid metabolism.”
BackgroundLupșor‐Platon, M. (2019) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-415
“28 No 3: 257-259 in NAFLD patients [17-19], but these are insufficiently accurate when used alone [20, 21].”
BackgroundCibler IRE1α dans le carcinome hépatocellulaire - une nouvelle piste thérapeutique ?
Vallée, D. (2019) · theses.fr (ABES) · doi:10.70675/7f0f7d18z2e64z471fz93b7z12498efca3c8 · Cited by 1
(2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328317a234
The complement system and cardiovascular disease: the CODAM study
Hertle, E. (2016) · Research Publications (Maastricht University) · doi:10.26481/dis.20160401eh
Günay, S., Paköz, Z. B., & Adanır, H. (2022) · Akdeniz Medical Journal · doi:10.53394/akd.976570
NONINVASIVE DIAGNOSTICS OF NON-ALCOHOLIC STEATOHEPATITIS
Калинин, А. Л., Tsitko, E. V., Сницаренко, Е. Н., & Хватик, Т. В. (2011) · Health and Ecology Issues · doi:10.51523/2708-6011.2011-8-1-18
Uddin, M. M., Shabnam, M., Islam, M. K., Afrooz, F., & Banik, G. C. (2024) · Journal of Medicine · doi:10.3329/jom.v25i1.70519 · Cited by 1
“16,19 CRP has a short life of around 18 hours.”
BackgroundNuñez, R. A. B., & Maquera, O. R. R. (2024) · Universidad Peruana de Ciencias Aplicadas (UPC) · doi:10.19083/tesis/671054
THE CONTRIBUTION OF NON-ALCOHOLIC FATTY LIVER DISEASE TO THE PROGRESSION OF ATHEROSCLEROSIS
Sadikova, S. I., & Khodjaeva, N. S. (2024) · The American Journal of Medical Sciences and Pharmaceutical Research · doi:10.37547/tajmspr/volume06issue06-02
Liu, C., Bai, Z., & Cheng, J. (2025) · World Journal of Public Health · doi:10.11648/j.wjph.20251003.29
Bolisetty, S. S., Prashanti, K. V., Juluri, V., Santhanam, J., Govindan, S., Mitra, T., Kumar, A. H. S. A., & Sundari, S. N. M. (2025) · Research Square · doi:10.21203/rs.3.rs-7662492/v1
Johnson, N. D., Wu, X., Still, C. D., Chu, X., Petrick, A. T., Gerhard, G. S., Conneely, K. N., & DiStefano, J. K. (2021) · Figshare · doi:10.6084/m9.figshare.15122268
Teixeira, A. R. D. S. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Nogueira, P. M. M., Marques, C. E. C., VIEIRA, B. C., Leite, N. C., Equi, C., Cardoso, A. C., Wajsbrot, N. B., do Nascimento, E. M., Pereira, B. D. B., de Oliveira, G. M. M., et al. (2026) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003140
Chen, S., Zhu, L., & Jiang, Y. (2026) · Abdominal Radiology · doi:10.1007/s00261-026-05414-3
Śledzińska, K., Polat, K., Kuchta, A., Dulak, J., Łoboda, A., Florczyk, U., Szczyrski, J., Bautembach-Minkowska, J., Meyer-Szary, J., Wernio, E., et al. (2026) · Pediatric Obesity · doi:10.1111/ijpo.70106
Vidé, J. (2015) · theses.fr (ABES) · doi:10.70675/f400b27fzebd7z42e6zbd92z8d70eebc3020 · Cited by 1
Patouraux, S. (2014) · theses.fr (ABES) · doi:10.70675/bea4ea3bzea9dz415cz8833z4550cabe679b
Silva, F. D. (2018) · theses.fr (ABES) · doi:10.70675/a1ef7558z4d24z4e76zb646zb00718717192
The roles of endoplasmic reticulum stress and Bax inhibitor-1 in non-alcoholic fatty liver disease
Lebeaupin, C. (2018) · theses.fr (ABES) · doi:10.70675/de500ab2z3c59z484dz8f58z7c3173626c42
Blanc, M. (2022) · theses.fr (ABES) · doi:10.70675/bd9df93bzbc68z496cz8abbz31ac769766eb · Cited by 1
Impact de l'élongase ELOVL5 sur la stéatose et l'inflammation au niveau hépatique
Vouilloz, A. (2023) · theses.fr (ABES) · doi:10.70675/6eb3b3cez17d4z4977z95b3z2a094b6ece36
Periodontitis and physical activity: a scoping review
Contreras-León, J., Herrera-Atoche, J. R., Carrillo-Ávila, B. A., Martínez-Aguilar, V. M., Díaz‐Zúñiga, J., & Melgar‐Rodríguez, S. (2026) · Frontiers in Oral Health · doi:10.3389/froh.2026.1786143
Penttilä, N. R. (2023) · UEF eRepo (University of Eastern Finland)
Metadata
- Authors
- Yoneda, M., Mawatari, H., Fujita, K., Iida, H., Yonemitsu, K., Kato, S., Takahashi, H., Kirikoshi, H., Inamori, M., Nozaki, Y., Abe, Y., Kubota, K., Saito, S., Iwasaki, T., Terauchi, Y., Togo, S., Maeyama, S., & Nakajima, A.
- Affiliations
- Yokohama City University Hospital (JP)
- Yokohama City University (JP)
- Kitakashiwa Rehabilitation General Hospital (JP)
- ORCID
- Venue
- Journal of Gastroenterology
- Published
- 2007-07-25
- Volume
- 42
- Issue
- 7
- Pages
- 573-582
- ISSN
- 0944-1174 (ISSN-L)
- 1435-5922
- OpenAlex
- W2060798922
- Cited by
- 294
- References
- 50
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 9 · 2023: 16 · 2022: 17 · 2021: 19 · 2020: 15 · 2019: 10 · 2018: 10 · 2017: 17 · 2016: 18 · 2015: 14 · 2014: 14 · 2013: 21 · 2012: 14
- FWCI
- 14.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- high-sensitivity C-reactive protein, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, hepatic steatosis, liver fibrosis severity, interleukin-6, inflammatory markers, disease progression
- MeSH terms
- Adult, C-Reactive Protein, Fatty Liver, Female, Hepatitis, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Prospective Studies, RNA, Messenger, Severity of Illness Index, Biomarkers, Interleukin-6, Gene Expression, Logistic Models, Reverse Transcriptase Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.